114 related articles for article (PubMed ID: 3289607)
1. Biochemical markers in multiple myeloma: a multivariate analysis.
Simonsson B; Källander CF; Brenning G; Killander A; Gronowitz JS; Bergström R
Br J Haematol; 1988 May; 69(1):47-53. PubMed ID: 3289607
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
3. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
4. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum beta 2-microglobulin in multiple myeloma.
Brenning G; Simonsson B; Källander C; Ahre A
Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
7. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
Brenning G; Wibell L; Bergström R
Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
[TBL] [Abstract][Full Text] [Related]
8. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Diem H; Fateh-Moghadam A; Lamerz R
Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
11. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.
Simonsson B; Källander CF; Brenning G; Killander A; Ahre A; Gronowitz JS
Br J Haematol; 1985 Oct; 61(2):215-24. PubMed ID: 4041368
[TBL] [Abstract][Full Text] [Related]
13. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
[TBL] [Abstract][Full Text] [Related]
14. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
[TBL] [Abstract][Full Text] [Related]
15. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.
Gronowitz JS; Bergström R; Nôu E; Påhlman S; Brodin O; Nilsson S; Källander CF
Cancer; 1990 Aug; 66(4):722-32. PubMed ID: 2167141
[TBL] [Abstract][Full Text] [Related]
16. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
18. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
19. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
[TBL] [Abstract][Full Text] [Related]
20. Serum thymidine kinase and beta-2 microglobulin in monoclonal gammopathies.
Ucci G; Riccardi A; Luoni R; Spriano P; Merlini G; Danova M; Cassano E; Molinari E; Ascari E
Tumori; 1987 Oct; 73(5):445-9. PubMed ID: 3318049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
